What is the role of pembrolizumab in the treatment of Hodgkin lymphoma (Hodgkin disease)?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

In March 2017, pembrolizumab, another monoclonal antibody to programmed cell death-1 protein (PD-1) gained accelerated approval from the FDA for cHL. It is indicated in adults and pediatric patients who have refractory cHL or have relapsed after 3 or more prior lines of therapy. Approval was based on data from the KEYNOTE-087 trial (n=210), which demonstrated an ORR with pembrolizumab averaging ~67% (95% CI: 62, 75), a CRR of 22%, and a PRR of 47%. The median follow-up time was 9.4 months. In the 145 patients who responded to treatement, the median duration of response was 11.1 months. [99]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!